Últimas noticias sobre Schmid Group (NASDAQ:SHMD) Bolsa

Schmid Group

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

SCHMID Group N.V. - Class A Ordinary Shares

Schmid Group NV

Shimano Inc

News

Financing

SAVE

Spirit Airlines Reports That On October 11, 2024 The Co Entered Into A Letter Agreement Which Modifies Its Existing Card Processing Agreement To Extend The 2025 Notes Extension Deadline From October 21, 2024 To December 23, 2024 And The Early Maturity Date From December 31, 2024 To March 3, 2025

Village Farms International, Inc. ("Village Farms" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that it is not in compliance with the minimum bid price requirement (NASDAQ Listing Rule) as the bid price for the Company's common shares closed below US $1.00 (the "Minimum Bid Requirement") from September 6, 2024 to October 17, 2024 (the "Notification").
The Notification has no immediate effect on the listing of the Company's common shares on the Nasdaq Capital Market. Under NASDAQ Listing Rule 5810(c)(3)(A), the Company has until April 16, 2025, a period of 180 calendar days from the date of Notification (the "Compliance Period") to regain compliance with the Minimum Bid Requirement. During the Compliance Period, Village Farms common shares will continue to trade on the Nasdaq Capital Market. If at any time before April 16, 2025, the bid price of Village Farms' common shares closes at or above US $1.00 per share for a minimum of 10 consecutive business days, it is expected that Nasdaq would notify the Company that it has regained compliance with the Minimum Bid Requirement.
In the event the Company does not regain compliance with the Minimum Bid Requirement by April 16, 2025, the Company may be eligible for an additional period of 180 calendar days to regain compliance or may be subject to delisting of its common shares from the Nasdaq Capital Market, at which time the Company may appeal the delisting determination to a Nasdaq Hearings Panel.

Village Farms International Received Notice From The Nasdaq That Is Not In Compliance With The Minimum Bid Price Requirement

<a href="https://www.globenewswire.com/Tracker?data=H2daQcf_I2GN6OmeR1xFdnTathsgecFtJTGfHE70PDJgU0nJIU-24KVPsKcirEazVMyl3-lQ46pm-zRu7H-YqA==">Celularity&nbsp;Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) (the "Company"), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that it has received a formal notice from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on October 16, 2024, indicating that the Company is subject to delisting due to its inability to timely file its Forms 10-Q for the the periods ended March 31, 2024, and June 30, 2024 (the "Forms 10-Q") within the prescribed 180-day compliance period. Nasdaq's notice has no immediate effect on the listing of the Company's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols "CELU" and "CELUW", respectively.
The Company will appeal the determination with the Nasdaq Hearings Panel prior to October 24, 2024, and request a hearing to present its plan to regain compliance and, if necessary, request a stay of suspension pending the hearing. However, there can be no assurance that Nasdaq will accept the plan, that the Company will regain compliance within any additional compliance period, or that the Company will maintain compliance with the other Nasdaq listing requirements.
The Company remains committed to regaining full compliance with Nasdaq's listing requirements. The Company has filed its annual report on Form 10-K for fiscal year 2023 within the compliance period and its quarterly report on Form 10-Q for the first quarter 2024 on October 16, 2024. Additionally, the Company intends to file its Form 10-Q for the second quarter 2024 within the coming weeks.

CELU

Celularity Receives Notice From Nasdaq; Confirms Intention To File An Appeal

<ul>
<li>The company delivered 57 aircraft in 3Q24 versus 43 a year ago</li>
<li>2 C-390 Millennium aircraft delivered during the quarter and 6-12 A-29 Super Tucanos orders</li>
<li>First E2 aircraft delivered to LOT Polish Airlines</li>
<li>US$ 22.7 billion company wide backlog, up more than 25% annually and at a 9-year high level</li>
<li>Defense &amp; Security backlog soared almost 70%</li>
</ul>
SÃO PAULO, Oct. 18, 2024 /PRNewswire/ --&nbsp;Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>, B3: EMBR3)))), a global leader in the aerospace industry, delivered a total of 57 jets in 3Q24 – an increase of 33% compared to the same period last year (yoy) and 24% over to the previous quarter (qoq). Commercial aviation delivered 16 jets and Executive aviation delivered another 41 jets. Meanwhile, Defense &amp; Security delivered 2 C-390 Millennium aircraft during the quarter – the first aircraft to Hungary and the seventh to Brazil.

Embraer-Empresa Brasileira De Aeronautica

Embraer Delivered 57 Aircraft In Q3 Versus 43 YoY And Reached A New $22.7B Backlog Record, Up More Than 25% Annually And At A 9-Year High Level

Oak Valley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVLY#NASDAQ">OVLY</a>) reported quarterly earnings of $0.89 per share. This is unchanged from the same period last year.

Earnings

OVLY

Oak Valley Q3 EPS $0.89, Same YoY

The Kentucky General Assembly's Administrative Regulation Review Subcommittee has officially approved a set of regulations for medical cannabis businesses ahead of the program's January 1, 2025 launch. 
These <a href="https://apps.legislature.ky.gov/law/kar/titles/915/">regulations</a> outline application fees, annual licensing costs, and safety compliance standards for businesses aiming to participate in Kentucky's budding medical cannabis market, <a href="https://www.kentuckytoday.com/news/medical-cannabis-regulations-approved/article_b457ecba-8c01-11ef-a5e4-9f32b53d2a41.html">reported</a> Kentucky Today.
Cultivators fall under four tiers, with non-refundable application fees ranging from $3,000 to $30,000, based on the <a href="https://www.benzinga.com/general/biotech/23/10/35504268/scaling-profits-with-multi-tier-cannabis-cultivation-growglides-lego-like-solution">scale of cultivation</a>. For processors and dispensaries, the fee is set at $5,000, while safety compliance facilities will pay $3,000. Once approved, annual fees range from $12,000 to $100,000 depending on the tier.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41405555/floridas-cannabis-amendment-record-spending-unlikely-alliances-and-criticism-from-the-catholic-c">Florida&#8217;s Cannabis Amendment: Record Spending, Unlikely Alliances, And Criticism From The Catholic Church</a>
Kentucky's Office of Medical Cannabis executive director, Sam Flynn said there&#8217;s huge interest in the program, with nearly 5,000 applicants submitting their proposals.
"The total number of applications was 4,998," Flynn stated, highlighting that 4,075 were dispensaries and 923 were cultivators, processors, or compliance facilities. 
The initial wave of applications generated an impressive $27.7 million in non-refundable fees.
However, Flynn noted that these fees represent a one-time revenue stream. To maintain program sustainability, patient fees &#8211; set at $25 for both initial applications and annual renewals &#8211; will help support ongoing costs. The potential need for additional general fund appropriations may arise in the future to cover shortfalls.
Kentucky recently awarded its first <a href="https://www.benzinga.com/markets/cannabis/24/09/41059061/kentucky-moves-closer-to-medical-cannabis-rollout-with-first-license-awarded-to-testing-lab">medical cannabis </a>license to a testing lab.
Meanwhile, Kentucky is gearing up for its next step, with plans to distribute licenses to cultivators and processors through a <a href="https://www.benzinga.com/markets/cannabis/24/09/41059061/kentucky-moves-closer-to-medical-cannabis-rollout-with-first-license-awarded-to-testing-lab">lottery system</a> set for October 28.
<ul>
<li>Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/10/41368890/florida-sheriff-backs-cannabis-legalization-amendment-im-a-conservative-with-strong-faith-and-fa"> Florida Sheriff Backs Cannabis Legalization Amendment: &#8216;I&#8217;m A Conservative With Strong Faith And Family Values&#8217;</a></li>
</ul>
Cover: AI generated image

Cannabis

Government

Regulations

Markets

Huge Interest In Medical Cannabis Licenses In Kentucky, Nearly 5,000 Applications, Fees Announced

Many investors still hold high regard for the <a href="https://www.marketbeat.com/stocks/sectors/computer-and-technology/">technology sector</a> in the United States today, which makes sense as the services PMI index is carrying most&mdash;if not all&mdash;of the economic growth left in the country, compared to the 23-month contraction in the <a href="https://www.marketbeat.com/stocks/sectors/manufacturing/">manufacturing sector</a>, as seen in that PMI index. However, not all technology sectors are equal.
The <a href="https://www.marketbeat.com/compare-stocks/semiconductor-stocks/">semiconductor and chipmaking</a> niche of the sector receives special attention, which has been present all of 2024 and extrapolated since the shortages seen since the COVID-19 pandemic. In recent quarters, all the pressure seems to have been placed on shares of Taiwan Semiconductor Manufacturing Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>), the global leader in chip sales with major customers all over the sector.
However, investors might have been concerned after seeing NVIDIA Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvidia#NASDAQ">NVIDIA</a>) sell-off after its last quarter, which announced a state of &quot;<a href="https://www.hindustantimes.com/business/nvidias-ceo-jensen-huang-says-new-chip-will-have-lots-and-lots-of-supply-101725536426366.html">lots and lots of supply</a>,&quot; according to its CEO, which would ultimately hurt margins and earnings per share (EPS). More recently, ASML Holding (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asml#NASDAQ">ASML</a>) stock sold off by over 17% in a single day after <a href="https://www.marketbeat.com/stock-ideas/asmls-earnings-miss-opens-door-for-savvy-investors/">missing booking guidance</a>.
<h3>Taiwan Semiconductor Stock Soars 12%: Strong Earnings and Growing Demand Fuel Rally</h3>
To ease some of the ASML and NVIDIA concerns, Taiwan Semiconductor stock rallied by over 12% in a single day following the blowout earnings results posted. This may have caused a surprise figure to outperform some of its peers during the quarter.
Investors <a href="https://www.marketbeat.com/stock-ideas/taiwan-semiconductor-stock-buy-now-or-wait-for-earnings/">would have been ready</a> for this rally by looking at a few metrics beforehand. Some of these metrics include the monthly revenue growth rate and the fact that markets were willing to pay a premium valuation only to get exposure to the company&#39;s future earnings, which is often a bullish sign.
Building on these views&nbsp;that investors enjoyed the rally, here&#39;s what investors can now keep in mind moving forward and decide whether there is still further upside left in Taiwan Semiconductor stock. To start with revenue, the&nbsp;<a href="https://pr.tsmc.com/english/news/3180" rel="noopener" target="_blank">company&#39;s earnings press release</a> shows a jump of 39% over the past 12 months.
Then, investors can lean on the fact that the company&#39;s net income jumped by 54% during the quarter to significantly boost potential valuation targets from Wall Street analysts. But that&#39;s all in the past; in order to accurately predict the stock&#39;s value, investors need to look into the future.
Easing some of the fears of demand from the industry, the company&#39;s CEO said, &quot;Demand is real, and I believe it&#39;s just the beginning,&quot; speaking of other peers in the space like NVIDIA. These words were quantified further after the statement, though management guidance to blow most expectations out of proportion.
Revenue projections, even after a 54% jump over the past quarter, are still expected to outpace current guidance projections. For the next quarter, Taiwan Semiconductor management expects to deliver up to $26.9 billion in revenues compared to the estimate of $24.9 billion.
Not only is revenue expected to rise by another double-digit rate, but here&#39;s where valuations can be boosted in the coming months. Gross margins are guided to land nearer to 57% against the former consensus of 54.7%, which speaks to the state of pricing power present in the industry as demand outpaces supply to help costs and prices.
<h3>Wall Street Weighs In On Taiwan Semiconductor Stock: What Investors Can Expect Next</h3>
Recently, analysts at Needham &amp; Co. decided to reiterate their &quot;Buy&quot; rating on Taiwan Semiconductor stock on the day of earnings. Still, their valuations seem a bit out of touch. They see the stock going to $210, which is still roughly a dollar lower than where it rallied.
More significant is the previous price target set by those at Susquehanna in August 2024. Those analysts saw a &quot;Positive&quot; rating for the stock, this time boosting their targets and <a href="https://www.marketbeat.com/stocks/NYSE/TSM/forecast/">valuation up to $250 a share</a> to call for a further 18.5% upside from where the stock trades today.
Realizing that the demand trends might favor more profitability and margins in the industry, bearish traders decided to step away from the market during the past quarter. Taiwan Semiconductor stock&#39;s short interest has declined from $5.6 billion at the peak of last quarter <a href="https://www.marketbeat.com/stocks/NYSE/TSM/short-interest/">to $4.5 billion today</a>.
As the stock rallies by double-digits this week, more short sellers might be forced to cover their positions and add additional buying pressure to a stock whose bullish momentum seems to just be getting started.
The article &quot;<a href="https://www.marketbeat.com/originals/taiwan-semiconductor-soars-on-earnings-with-more-room-to-run/">Taiwan Semiconductor Soars on Earnings With More Room to Run</a>&quot; first appeared on MarketBeat.

Tech

General

ASML

NVIDIA

Taiwan Semiconductor Soars On Earnings With More Room To Run

The Procter &amp; Gamble Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pg#NYSE">PG</a>) issued its fiscal 2025 first-quarter earnings report on Friday, missing sales and net income estimates but topping adjusted profit estimates.&nbsp;
<h3>Fiscal First Quarter Highlights</h3>
For the quarter ended on September 30th, P&amp;G reported&nbsp;net sales&nbsp;dropped&nbsp;1% to $21.74 billion
Putting away&nbsp;&nbsp;foreign exchange, acquisitions and divestitures,&nbsp;organic revenue grew 2% helped by higher prices. However, volume was flat, which is a better reflection of sales. While in the U.S., P&amp;G&rsquo;s volume grew in eight of its 10 categories, Greater China&nbsp;told an entirely diferent story with both its hair care and oral care segments reporting volume declines.&nbsp;
Overall, health care and baby, feminine and family care divisions all reported 1% volume declines, the beauty business experienced a volume decline of 2%, while organic sales of the skin care segment tumbled more than 20%. Supported by innovation, grooming division was a rare bright spot with volume growth of 4%.&nbsp;Fabric and home care reported a mild volume rise of 1%.&nbsp;
Getting down to the bottom line, net income attributable to the company amounted to $3.96 billion, or $1.61 per share, with adjusted earnings per share amounting to $1.93 per share.
After several price hikes over the last few years, P&amp;G has seen demand for its products drop. The last quarter was the first time in more than two years that P&amp;G experienced an increase in volume, but it was apparently short-lived.&nbsp;With the falling&nbsp;global birth rate continues to drop, P&amp;G has been trying to push consumers to buy more expensive baby care items&nbsp;but organic sales of the baby care segment fell by mid-single digits as that strategy cannot always make up for the volume decline.&nbsp;
P&amp;G remains on track to deliver its guidance.
P&amp;G reiterated its fiscal 2025&nbsp;guidance, expecting revenue growth between&nbsp;2% and 4% and net earnings per share ranging from $6.91 to $7.05. But, P&amp;G CFO&nbsp;CFO Andre Schulten noted that the Chinese market will continue to be weak for quarters to come.&nbsp;The macroeconomic environment in the U.S. that accounts for almost half of total sales remains challenging with uncertainty pushing consumers to discount-offering rivals and cheaper brands. Its rival in packaged foods manufucating, Nestle S.A. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/nsrgy#OTC">NSRGY</a>) lowered its annual sales outlook. Nestle expects the weak demand environment to continue. After reporting dissapointing sales, Nestle announced changes corporate structure changes, aiming to streamline its operating structure. With the pandemic and the war in Ukraine, the packaged foods industry is not alone in struggling with soaring costs as prices of everything from raw materials to packaging continues to go through the roof. Even a Swiss giant like Nestle is dealing with a very painful and unprecedented reset as just like P&amp;G, it faces not only a demand slowdown&nbsp;but a significantly weakened consumer in the eyes of unprecedented uncertainty that has been lingering for quite some time, without any signs of going away.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Nestle Sponsored representing Registered Shares Series B

NSRGY

Procter & Gamble Faces A Weakened Demand In Both The U.S. And China

In the winter of 2023, combat medic Ihor Kholodylo faced a life-altering event on Ukraine&#8217;s eastern front. A shell from a Russian tank struck his medical evacuation van, leaving him severely injured. Though Kholodylo survived, the psychological toll was profound. Despite healing from physical injuries, he was left with a debilitating stutter, a symptom of post-traumatic stress disorder (PTSD).
As Kyiv Post <a href="https://www.kyivpost.com/post/40573">reported</a>, Kholodylo, a psychologist by profession, recognized that traditional <a href="https://www.benzinga.com/topic/ptsd">PTSD</a> treatments, such as talk therapy, would take too long. His search for faster relief led him to an emerging treatment: <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine-assisted therapy</a> (KAP). Conducted at the Expio Clinic in Kyiv, Kholodylo&#8217;s experience with ketamine revealed buried traumas from his time on the frontlines. After several sessions, his stutter vanished.
&#8220;I needed something different and more direct,&#8221; Kholodylo explained. "The concept [of ketamine] made sense to me, it helped access the unconscious."
Kholodylo is now advocating for wider access to KAP for Ukrainian veterans. He envisions <a href="https://www.benzinga.com/topic/ketamine">ketamine</a> not only as a treatment for PTSD but as a preventive measure for soldiers between combat assignments.
<h3 class="wp-block-heading">Ketamine's Role In PTSD Treatment</h3>
Ketamine, once known as an anesthetic, <a href="https://www.benzinga.com/markets/cannabis/24/05/38652184/ketamine-assisted-psychotherapy-offers-hope-in-the-treatment-of-chronic-pain-and-depression-here">has shown significant promise</a> for treating mental health conditions like PTSD. Unlike traditional antidepressants, which can take weeks to show results, ketamine works within hours, providing immediate relief from anxiety, depression and traumatic symptoms. According to <a href="https://www.benzinga.com/partner/biotech/24/05/38941052/revolutionizing-mental-healthcare-with-the-rise-of-ketamine-and-psychedelic-therapies">several studies</a>, ketamine acts on the brain's glutamate system, which helps reset abnormal neural activity, a key factor in PTSD.
Dr. Vladislav Matrenitsky, founder of the Expio Clinic, emphasizes the scientific foundation of ketamine's effectiveness. "We know why it works in terms of brain chemistry and physiology," he says, explaining that ketamine restores neural functioning and helps patients process trauma without re-traumatization.
At Expio, more than 300 clients have undergone KAP since 2018, with military veterans becoming an increasing portion of the patient base following the <a href="https://www.benzinga.com/topic/russia-ukraine-war">2022 Russian invasion</a>. Matrenitsky reports that 70% of patients experience improvement, with ketamine showing a 50% greater impact than conventional therapy.
<h3 class="wp-block-heading">Scaling Ketamine For Ukrainian Veterans</h3>
Heal Ukraine Trauma (HUT), an NGO focused on mental health, has trained eight Ukrainian psychologists and psychiatrists in group ketamine therapy. According to HUT executive director Elise Wilson, the group model allows more veterans to be treated, fostering a sense of community among them.
"The group therapy model not only allows for more individuals to be treated but also creates a supportive network that extends beyond the therapy sessions," Wilson told the Kyiv Post. HUT plans to train 64 more practitioners in 2025, hoping to eventually treat up to 9,600 veterans annually.
While KAP shows promise, advocates stress that ketamine is not a &#8220;silver bullet.&#8221; Wilson emphasizes that ketamine should be integrated into a comprehensive care framework that includes psychotherapy and long-term support.
<h3 class="wp-block-heading">A Path To National Recovery</h3>
As Ukraine grapples with the scars of war, <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted therapy</a> offers new hope. Oleh Orlov, chair of the Ukrainian Psychedelic Research Association, views this approach as not just a medical advancement but a crucial step toward national recovery.
"For Ukraine, this represents not just a medical advancement but a crucial step towards emotional resilience," says Orlov.
To this end, <a href="https://www.benzinga.com/topic/volodymyr-zelensky">President Volodymyr Zelensky</a>, <a href="https://www.benzinga.com/markets/cannabis/24/02/37167633/ukraines-zelensky-signs-medical-cannabis-bill-to-help-those-suffering-from-trauma-amid-war-with-">signed a bill on medical cannabis</a> early this year. But, although several studies have <a href="https://www.benzinga.com/markets/cannabis/23/11/35735382/veterans-day-can-psychedelic-treatment-help-stem-ptsd-related-suicides-among-veterans">confirmed the potential</a> of cannabis and psychedelics to treat PTSD, the country&#8217;s law <a href="https://www.benzinga.com/markets/cannabis/24/08/40556985/ptsd-patients-could-be-left-behind-as-ukraines-medical-marijuana-law-takes-effect-and-more-canna">does not explicitly list this condition</a> for which the plant can be prescribed, as the Ministry of Health refused calls to include it.&nbsp;
 &#8220;We worked hard to include more conditions, but the Ministry of Health has taken a conservative approach,&#8221; said Hanna Hlushchenko, founder of the Ukrainian Cannabis Consulting Group. &#8220;For example, we pushed for the inclusion of conditions like insomnia and PTSD, but these were not added"
Cover image made with AI

Psychedelics

Eurozone

Ukraine's Military Veterans Turn To Ketamine For PTSD Treatment As Advocacy Grows

<ul>
<li>Under Armour, a Maryland-based sports apparel company, was experiencing rapid growth at the turn of the last decade.</li>
<li>In April 2016, Under Armour reported first-quarter earnings, marking its 24th consecutive quarter of over 20% revenue growth.</li>
<li>The company also predicted strong sales growth in the upcoming quarters.</li>
<li>However, in January 2017, Under Armour announced disappointing quarterly earnings and the unexpected resignation of its CFO, causing the stock to drop by more than 25% in just one day.</li>
<li>Shortly after, shareholders filed a lawsuit, claiming the company misled them about its financial health and revenue growth.</li>
<li>Under Armour recently agreed to pay a massive $434 million settlement to investors to resolve the lawsuit. Affected investors can now <a href="https://11thestate.com/cases/underarmour-investor-settlement">file a claim</a> to receive the payout.</li>
</ul>
<h3 class="wp-block-heading has-medium-font-size">Overview</h3>
During Under Armour, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) expansion phase, the company claimed it could sustain a 20% revenue growth for a long time. However, it later emerged that management hid issues with meeting these expectations due to declining demand and used questionable accounting practices to cover up the company's struggles. These claims were also backed by a separate investigation from the Securities and Exchange Commission. After years of legal disputes, the company has agreed to pay $434 million to affected shareholders over this situation.
<h3 class="wp-block-heading has-medium-font-size">Background</h3>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<cite>"Our first quarter revenues grew 30%, with the growth coming from every facet of our business. And to be clear, that 30% number was no accident. When Stephen Curry decided to average 30 points this season to take the scoring title while wearing the number 30, we thought that putting up 30% growth on our end was the best way for us to demonstrate our pride and support of Stephen and the Warriors." – Kevin Plank (Q1 2016 earnings call)</cite></blockquote>
Kevin Plank, the company's founder, served as the CEO during this growth phase of the company. The growth of the company was fueled by sportswear, which has been one of the company's principal products since its establishment in 1996. By 2014, the company reached a peak as it became the second-largest sportswear company in the United States by revenue. Committed to being positioned in the market at the high end and leveraging its cutting-edge technology on fabrics, Under Armour achieved 26 consecutive quarters of 20%+ YoY revenue growth from Q2 2010 to Q3 2016. The company's management promised a 20% growth in the upcoming quarters as well. However, Under Armour fell short of these expectations and, compounding the issue, the company&#8217;s CFO also left. These events shook investor confidence, causing the stock price to drop over 25% in a single day in January 2017.

<h3 class="wp-block-heading has-medium-font-size">Under Armour's Rosy Promises Met With Reality</h3>
After the third quarter of 2016, Under Armour began to see a significant decline in demand, particularly in its most profitable segment at the time: apparel. The company struggled to keep up with the rising &#8220;athleisure&#8221; trend, leading consumers to seek alternatives from its competitors.
In January 2017, when Under Armour announced its Q4 2016 earnings, investors were disappointed by weaker-than-expected sales growth. To make matters worse, CFO Lawrence Molloy also left the company, leading to a 26% drop in stock price on January 31, 2017. As shown below, Under Armour&#8217;s revenue growth never fully recovered to the levels seen between 2010 and 2016, highlighting that the company's business was already weakening in 2016, despite its continued promises of growth.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="626" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184219/tg_image_1594745250-1-1024x626.png" alt="" class="wp-image-2549" style="width:674px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184219/tg_image_1594745250-1-1024x626.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184219/tg_image_1594745250-1-300x184.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184219/tg_image_1594745250-1-768x470.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184219/tg_image_1594745250-1.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Under Armour&#8217;s financial troubles, despite management&#8217;s promises, led to a shareholder lawsuit in 2017. While Under Armour asserted strong demand for its products, signs of trouble were apparent, such as the bankruptcy of The Sports Authority. The lawsuit highlighted the company&#8217;s inaccurate claims of achieving 20% YoY revenue growth amid rising inventory levels. This situation forced Under Armour to lower its prices significantly, damaging its reputation as a premium sports apparel brand while competitors like Nike maintained higher prices.
The suit also raised concerns about Under Armour&#8217;s accounting practices, with accusations that the company inflated its financial performance by pulling revenue from future quarters. This led to the SEC investigation, which discovered that Under Armour had not disclosed its strategy of accelerating $408 million in orders for the second half of 2015, further casting doubt on its financial reporting.
The company's former executives later revealed that Under Armour frequently pressured retailers to take products early and shifted goods meant for factory stores to off-price chains to boost end-of-quarter sales. These tactics, along with other questionable practices, helped the company maintain its sales growth streak.
After the investigation, Under Armour was charged with securities fraud for withholding key information in its SEC filings.&nbsp; In 2021, to settle the case with the SEC, Under Armour agreed to a payment of $9 million.&nbsp;
These financial missteps have had a lasting impact. After reaching a high of over $50 in 2015 amid strong growth and rosy promises, once a high-flying stock, UAA is currently trading at around $8.50. Under Armour stock has lost more than 74% of its market value in the last 10 years.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="852" height="392" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184420/image-14.png" alt="" class="wp-image-2550" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184420/image-14.png 852w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184420/image-14-300x138.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184420/image-14-768x353.png 768w" sizes="(max-width: 852px) 100vw, 852px" /></figure>
<h3 class="wp-block-heading has-medium-font-size">Resolving The Case</h3>
Under Armour continues to face financial challenges, reporting a 3% YoY decline in revenue for the most recent financial year. Its operating income has fallen from $408.5 million in 2015 to just $221.5 million in the past year, highlighting difficulties in staying profitable amid increasing competition.
Despite these issues, Under Armour&#8217;s directors and management have consistently denied any violations of securities laws, asserting that their actions were normal and lawful. They claim that no material misrepresentations or omissions were made in their filings. Mehri Shadman, the company&#8217;s chief legal officer and corporate secretary, further clarified the management&#8217;s position:&nbsp;
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<cite>"We firmly believe that our sales practices, accounting practices, and disclosures were appropriate, and deny any wrongdoing in this case."&nbsp;</cite></blockquote>
In a positive turn for shareholders facing significant losses, Under Armour reached a settlement in June 2024, agreeing to pay $434 million to affected investors. If you invested in Under Armour between 2015 and 2019, you can <a href="https://11thestate.com/cases/underarmour-investor-settlement">claim part</a> of this settlement to recover some of your losses.

The Price Of Overpromising: Under Armour's Legal Battle

The five years after Canada legalized recreational cannabis have produced enough data for researchers to look at important questions like how <a href="https://www.benzinga.com/markets/cannabis/24/06/39277643/legal-weed-less-crime-fbi-data-shows-surprising-benefits-of-cannabis-legalization">organized crime</a> is affected by legalization, or not.
A recent <a href="https://onlinelibrary.wiley.com/doi/full/10.1111/soin.12619">study</a>, published in Sociological Inquiry, explores how the shift to a legal market has reshaped criminal enterprises once heavily involved in the illicit cannabis trade.
<h3 class="wp-block-heading">Key Findings On Organized Crime &amp; Cannabis</h3>
The research, conducted by scientists Martin Bouchard, Naomi Zakimi -of Simon Fraser University-, and Benoît Gomis -of the University of Toronto&#8211; shows that the <a href="https://www.benzinga.com/markets/cannabis/24/08/40558227/cannabis-sales-in-canada-decline-sharply-whats-behind-the-drop">legal cannabis market</a> now dominates in Canada, accounting for over 71% of household expenditures on cannabis as of 2023. However, nearly 29% of the market still belongs to <a href="https://www.benzinga.com/markets/cannabis/24/09/40837305/new-partnership-targets-unlicensed-cannabis-shops-in-new-york-heres-how">unlicensed sellers</a>.
Some of the study's most notable findings include:
<ol>
<li>A Shrinking Illicit Market: Legal cannabis sales have steadily increased since legalization, gradually cutting into the black market.</li>
<li>Organized Crime&#8217;s Resilience: Criminal organizations are adapting, either by diverting legal cannabis into the unlicensed market or shifting their operations to illegal drugs.</li>
<li>Consumer Challenges: High prices, inconsistent quality, and limited accessibility in the legal market continue to drive some consumers toward cheaper, unlicensed alternatives.</li>
<li>Cross-Border Smuggling: Despite legalization, some unlicensed products are smuggled out of Canada into markets abroad, particularly in the U.S.</li>
<li>Shifting Criminal Focus: With cannabis becoming less profitable, many criminal groups are focusing on more dangerous drugs like opioids.</li>
</ol>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/06/39277643/legal-weed-less-crime-fbi-data-shows-surprising-benefits-of-cannabis-legalization">Legal Weed = Less Crime: FBI Data Shows Surprising Benefits Of Cannabis Legalization</a>
<h3 class="wp-block-heading">Methods And Indicators</h3>
To draw these conclusions, the researchers conducted a comprehensive review of more than 5,000 sources, including academic papers, media reports and government publications.
The key indicators used to assess the impact of cannabis legalization on organized crime include several metrics, such as price comparison between legal and illicit cannabis markets, supply-demand balance and cash circulation.
Lower legal cannabis prices tend to pull consumers away from illegal sources, so price monitoring is crucial. Cannabis demand estimates and legal supply are also analyzed to measure how well the legal market meets consumption needs, which could reduce reliance on the illicit market. Other indicators include tracking <a href="https://www.benzinga.com/markets/cannabis/24/01/36685934/why-is-the-illicit-cannabis-market-still-outselling-cool-legal-weed-dispensaries-let-me-count-th">illicit cannabis</a> seizures by law enforcement, examining criminal justice data for organized crime ties and analyzing cash circulation as an indicator of illegal market transactions.
These methods, along with interviews and internal documents, provide a more nuanced understanding of how organized crime has responded to legalization.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Recommendations For Policy Makers</h3>
One key finding is that the link between <a href="https://www.benzinga.com/markets/cannabis/24/08/40591338/canadas-cannabis-growth-slowed-due-to-federal-gov-inaction-key-industry-leader-says">unlicensed</a> and licensed cannabis is persistent and complex.
&#8220;Policies and law enforcement interventions aiming to address the illicit cannabis trade in Canada may indeed have consequences on legal cannabis production, sales, and consumption as well. The legal market may need to compete by learning from the consumer preferences established in the illegal market.&#8221;
Thus there&#8217;s a need for a comprehensive approach.
&#8220;Regulators and politicians would do well to measure expectations: the illegal activities along cannabis supply chains will persist and eliminating them altogether is an unrealistic goal,&#8221; the researchers add.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41034042/fbi-report-over-200-000-people-were-arrested-for-cannabis-related-violations-in-2023-how-is-that">FBI Report Over 200,000 People Were Arrested For Cannabis-Related Violations In 2023: How Is That Possible?</a></li>
</ul>
Cover: Courtesy of the California Department of Cannabis Control.

Politics

Legal

How Does Cannabis Legalization Affect Organized Crime? New Research Sheds Light

In the preceding three months, 8 analysts have released ratings for Webster Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Webster Finl, revealing an average target of $57.62, a high estimate of $63.00, and a low estimate of $51.00. This current average reflects an increase of 4.29% from the previous average price target of $55.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1729285270_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Webster Finl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$59.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$54.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Webster Finl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Webster Finl compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Webster Finl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Webster Finl's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WBS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Webster Finl analyst ratings.</a>
<h2>About Webster Finl</h2>
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
<h3>Webster Finl: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Webster Finl displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.97%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Webster Finl's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 28.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.17%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Webster Finl's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.24%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Webster Finl's debt-to-equity ratio is below the industry average. With a ratio of 0.45, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Navigating 8 Analyst Ratings For Webster Finl

In the preceding three months, 14 analysts have released ratings for M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for M&amp;T Bank, revealing an average target of $203.64, a high estimate of $228.00, and a low estimate of $165.00. This upward trend is evident, with the current average reflecting a 12.65% increase from the previous average price target of $180.77.
<img src="https://www.benzinga.com/files/images/story/2024/1729285217_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of M&amp;T Bank by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$190.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$218.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$216.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$228.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$208.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Bill Carcache</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$210.00</td>
<td>-</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$183.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$188.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Frank Schiraldi</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$164.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to M&amp;T Bank. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of M&amp;T Bank compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for M&amp;T Bank's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of M&amp;T Bank's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MTB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on M&amp;T Bank analyst ratings.</a>
<h2>Get to Know M&amp;T Bank Better</h2>
M&amp;T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
<h3>Financial Insights: M&amp;T Bank</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: M&amp;T Bank's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 1.3%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: M&amp;T Bank's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 28.9%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.58%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): M&amp;T Bank's ROA stands out, surpassing industry averages. With an impressive ROA of 0.32%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: M&amp;T Bank's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.54, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

M&T Bank Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)

WIIM

The Cigna Group shares are trading lower after a report suggesting the company has resumed merger discussions with Humana after the conversation ended last year.

Canadian cannabis edibles company City View Green Holdings Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CVGR#CSE">CVGR</a>) (OTCPK:CVGRF) announced Thursday it plans to raise gross proceeds of up to CA$1 million($730,000) through a non-brokered private placement of up to 100 million units at a price of CA$0.01 per unit.
Under the placement, each unit will include one company share and half a warrant. Two halves make a full warrant, allowing the holder to buy one company share at CA$0.05 per share for up to three years after the issue date. If the average closing price of the company&#8217;s shares on the CSE equals or exceeds CA$0.055 for 10 consecutive trading days, starting one year after the closing, the company may shorten the warrant&#8217;s expiry date to 30 days after notifying holders.
City View Green plans to use the net proceeds from the placement for general working capital purposes.
The non-brokered private placement is subject to regulatory approvals. The company will pay finders&#8217; fees to eligible finders in connection with the private placement, in compliance with applicable securities laws and CSE policies. The securities issued in the private placement will be subject to a four-month and one-day hold period, in accordance with Canadian securities laws.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/10/41394513/sold-out-before-hitting-shelves-why-did-ayr-wellness-snatch-up-this-local-cannabis-brand">Sold Out Before Hitting Shelves: Why Did AYR Wellness Snatch Up This Local Cannabis Brand?</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Additionally, City View Green entered into a marketing and consulting agreement with the arm&#8217;s-length marketing firm Outside The Box Capital Inc. of Oakville, Ontario, to provide marketing and investor relations services, including social media and online media distribution. In connection with this engagement, starting on Oct. 15, 2024 and ending on Feb. 15, 2025, the company will pay OTBC a cash fee of $25,000 per month to a maximum of $75,000 over the term plus applicable taxes.
In April, City View Green announced it has <a href="https://www.newsfilecorp.com/release/205820/City-View-Green-Holdings-Inc.-Exits-Retail-Cannabis-Through-Ownership-in-Budd-Hutt-Announces-Director-Resignation">exited the retail cannabis space</a> through ts ownership in Budd Hutt, which relinquished its last two licenses and no longer operates in the Province of Alberta.
In November 2023, the company revealed it plans to review its strategy following June's working capital deficiency of almost CA$3.9 million and accumulated deficit of CA$44 million, <a href="https://www.greenmarketreport.com/city-view-green-seeks-c1m-after-alberta-retail-exit/">writes</a> Green Market's Adam Jackson. City View Green is yet to generate any revenue from its edibles operations.
<h2 class="wp-block-heading">Price Action</h2>
City View Green shares closed Friday&#8217;s market session flat at $0.0051 per share.
 Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41388261/revolutionizing-cannabis-edibles-ascends-new-thc-cannabinoid-blends-now-available-in-this-east-c">Revolutionizing Cannabis Edibles: Ascend&#8217;s New THC-Cannabinoid Blends Now Available In This East Coast Market</a></li>
</ul>
Photo: Courtesy of&nbsp;HTWE&nbsp;via Shutterstock&nbsp;

CSE:CVGR

CVGRF

Canadian Cannabis Edibles Producer City View Green To Raise $730K Via Private Placement

Humana shares are trading higher after a report suggesting Cigna has resumed merger discussions with the company after the conversation ended last year.

Whales with a lot of money to spend have taken a noticeably bearish stance on Citigroup.
Looking at options history for Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) we detected 41 trades.
If we consider the specifics of each trade, it is accurate to state that 39% of the investors opened trades with bullish expectations and 51% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $1,005,393 and 36, calls, for a total amount of $2,928,597.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $42.5 to $75.0 for Citigroup during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Citigroup options trades today is 14959.83 with a total volume of 47,452.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Citigroup's big money trades within a strike price range of $42.5 to $75.0 over the last 30 days.
<h3>Citigroup Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729284335_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$4.95</td>
<td>$62.50</td>
<td>$814.7K</td>
<td>14.6K</td>
<td>3.2K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.55</td>
<td>$13.5</td>
<td>$13.5</td>
<td>$50.00</td>
<td>$472.5K</td>
<td>39.1K</td>
<td>352</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.3</td>
<td>$13.25</td>
<td>$13.25</td>
<td>$50.00</td>
<td>$198.7K</td>
<td>39.1K</td>
<td>761</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.3</td>
<td>$13.25</td>
<td>$13.25</td>
<td>$50.00</td>
<td>$198.7K</td>
<td>39.1K</td>
<td>611</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$15.8</td>
<td>$15.7</td>
<td>$15.8</td>
<td>$47.50</td>
<td>$145.3K</td>
<td>23.9K</td>
<td>2.1K</td>
</tr>
</tbody>
</table>

<h3>About Citigroup</h3>
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
In light of the recent options history for Citigroup, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Citigroup Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 13,599,539, with C's price down by -1.75%, positioned at $62.85.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 89 days.</li>
</ul>
<h3>What Analysts Are Saying About Citigroup</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $82.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Citigroup, targeting a price of $64. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Citigroup, maintaining a target price of $78. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Citigroup with a target price of $86. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Citigroup, maintaining a target price of $92. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Citigroup with a target price of $91. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Citigroup, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Smart Money Is Betting Big In Citigroup Options

Financial giants have made a conspicuous bearish move on United Airlines Holdings. Our analysis of options history for United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) revealed 59 unusual trades.
Delving into the details, we found 42% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 18 were puts, with a value of $4,003,104, and 41 were calls, valued at $5,898,846.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $38.0 to $90.0 for United Airlines Holdings during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for United Airlines Holdings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United Airlines Holdings's whale activity within a strike price range from $38.0 to $90.0 in the last 30 days. 
<h3>United Airlines Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729284330_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$9.15</td>
<td>$9.1</td>
<td>$9.15</td>
<td>$75.00</td>
<td>$935.2K</td>
<td>5.6K</td>
<td>2.5K</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.3</td>
<td>$5.25</td>
<td>$5.25</td>
<td>$75.00</td>
<td>$368.5K</td>
<td>17.1K</td>
<td>2.2K</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$11.35</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$65.00</td>
<td>$340.5K</td>
<td>6.5K</td>
<td>825</td>
</tr>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$9.3</td>
<td>$9.15</td>
<td>$9.15</td>
<td>$75.00</td>
<td>$334.9K</td>
<td>5.6K</td>
<td>2.5K</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$5.25</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$75.00</td>
<td>$329.9K</td>
<td>17.1K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About United Airlines Holdings</h3>
United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large US peers.
<h3>United Airlines Holdings's Current Market Status</h3>
<ul>
<li>With a volume of 8,318,667, the price of UAL is up 0.78% at $73.9. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 95 days.</li>
</ul>
<h3>What The Experts Say On United Airlines Holdings</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $83.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on United Airlines Holdings, which currently sits at a price target of $70. 
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on United Airlines Holdings, which currently sits at a price target of $75. 
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on United Airlines Holdings with a target price of $100. 
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on United Airlines Holdings, which currently sits at a price target of $85. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for United Airlines Holdings, targeting a price of $88. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest United Airlines Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of United Airlines Holdings's Latest Options Trends

Whales with a lot of money to spend have taken a noticeably bearish stance on Synopsys.
Looking at options history for Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) we detected 21 trades.
If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $423,980 and 16, calls, for a total amount of $811,190.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $420.0 and $610.0 for Synopsys, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Synopsys's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Synopsys's significant trades, within a strike price range of $420.0 to $610.0, over the past month.
<h3>Synopsys Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729284326_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNPS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$55.0</td>
<td>$50.8</td>
<td>$50.8</td>
<td>$420.00</td>
<td>$213.3K</td>
<td style="text-align: right;">80</td>
<td style="text-align: right;">42</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.3</td>
<td>$61.0</td>
<td>$61.0</td>
<td>$600.00</td>
<td>$91.5K</td>
<td style="text-align: right;">150</td>
<td style="text-align: right;">64</td>
</tr>
<tr>
<td>SNPS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$31.9</td>
<td>$31.4</td>
<td>$31.6</td>
<td>$510.00</td>
<td>$69.5K</td>
<td style="text-align: right;">103</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>SNPS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$31.9</td>
<td>$31.5</td>
<td>$31.5</td>
<td>$510.00</td>
<td>$63.0K</td>
<td style="text-align: right;">103</td>
<td style="text-align: right;">72</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$61.0</td>
<td>$60.0</td>
<td>$60.0</td>
<td>$600.00</td>
<td>$60.0K</td>
<td style="text-align: right;">150</td>
<td style="text-align: right;">116</td>
</tr>
</tbody>
</table>

<h3>About Synopsys</h3>
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Following our analysis of the options activities associated with Synopsys, we pivot to a closer look at the company's own performance.
<h3>Where Is Synopsys Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 854,725, with SNPS's price up by 0.46%, positioned at $507.03.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 40 days.</li>
</ul>
<h3>What Analysts Are Saying About Synopsys</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $660.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Berenberg downgraded its rating to Buy, setting a price target of $660. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Synopsys, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

SNPS

Behind the Scenes of Synopsys's Latest Options Trends

<a href="https://www.bloomberg.com/news/articles/2024-10-18/cigna-resumes-merger-discussions-with-humana-after-talks-ended-last-year?srnd=phx-deals">https://www.bloomberg.com/news/articles/2024-10-18/cigna-resumes-merger-discussions-with-humana-after-talks-ended-last-year?srnd=phx-deals</a>
&nbsp;

'Cigna Resumes Merger Discussions With Humana After Talks Ended Last Year' - Bloomberg

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out with our coverage of all the latest news happening on Thursday!



We&rsquo;re knee-deep in earnings seasons as several companies release results for the first quarter of 2024 today.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Emergent BioSolutions (NYSE:<a href="https://investorplace.com/stock-quotes/ebs-stock-quote/">EBS</a>) stock is rocketing close to 70% alongside <a href="https://www.nasdaq.com/press-release/emergent-biosolutions-reports-first-quarter-2024-financial-results-2024-05-01">strong Q1 earnings</a>.</li>



<li>Carvana (NYSE:<a href="https://investorplace.com/stock-quotes/cvna-stock-quote/">CVNA</a>) shares are soaring more than 37% alongside its <a href="https://finance.yahoo.com/news/carvana-announces-record-first-quarter-201000815.html">Q1 2024 earings</a>.</li>



<li>Syra Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/syra-stock-quote/">SYRA</a>) stock is surging over 34% after announcing the date for its <a href="https://www.nasdaq.com/press-release/syra-health-to-discuss-first-quarter-2024-financial-results-2024-05-01">next earnings report</a>.</li>



<li>Aspen Aerogels (NYSE:<a href="https://investorplace.com/stock-quotes/aspn-stock-quote/">ASPN</a>) shares are increasing more then 26% after beating <a href="https://www.zacks.com/amp/stock/news/2266441/aspen-aerogels-aspn-surpasses-q1-earnings-and-revenue-estimates">Q1 EPS and revenue estimates</a>. </li>



<li>Tungray Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/trsg-stock-quote/">TRSG</a>) stock is gaining over 25% on Thursday morning.</li>



<li>Enovix (NASDAQ:<a href="https://investorplace.com/stock-quotes/envx-stock-quote/">ENVX</a>) shares are rising more than 23% after releasing its <a href="https://www.globenewswire.com/news-release/2024/05/01/2873598/0/en/Enovix-Announces-First-Quarter-2024-Financial-Results.html">Q1 earnings results</a>.</li>



<li>SCHMID Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHMD#NASDAQ">SHMD</a>) stock is climbing over 23% following its <a href="https://finance.yahoo.com/news/schmid-group-closes-business-combination-133500737.html">public debut yesterday</a>.</li>



<li> Pulmonx (NASDAQ:<a href="https://investorplace.com/stock-quotes/lung-stock-quote/">LUNG</a>) shares are heading more than 23% higher after <a href="https://www.msn.com/en-us/money/markets/lung-stock-earnings-pulmonx-beats-eps-beats-revenue-for-q1-2024/ar-AA1o0CfW?ocid=finance-verthp-feeds">beating EPS and revenue estimates</a> in Q1.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) stock is jumping over 21% on Thursday morning.</li>



<li>Evolus (NASDAQ:<a href="https://investorplace.com/stock-quotes/eols-stock-quote/">EOLS</a>) shares are up more than 20% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Fastly (NYSE:<a href="https://investorplace.com/stock-quotes/fsly-stock-quote/">FSLY</a>) stock is plummeting over 33% on a <a href="https://finance.yahoo.com/news/fastly-announces-first-quarter-2024-200500341.html">weak earnings forecast</a>.</li>



<li>Freshworks (NASDAQ:<a href="https://investorplace.com/stock-quotes/frsh-stock-quote/">FRSH</a>) shares are diving nearly 29% as its <a href="https://finance.yahoo.com/news/freshworks-inc-frsh-q1-2024-213448310.html">founder and CEO steps down</a>.</li>



<li>Remitly Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/rely-stock-quote/">RELY</a>) stock is tumbling more than 16% alongside its <a href="https://www.tipranks.com/news/company-announcements/remitly-global-unveils-new-investor-presentation-update">most recent earnings report</a>.</li>



<li>Etsy (NASDAQ:<a href="https://investorplace.com/stock-quotes/etsy-stock-quote/">ETSY</a>) shares are taking an over 14% beating as <a href="https://finance.yahoo.com/video/etsy-stock-falling-q1-earnings-203137769.html">headwinds affected Q1 earnings</a>.</li>



<li>IM Cannabis (NASDAQ:<a href="https://investorplace.com/stock-quotes/imcc-stock-quote/">IMCC</a>) stock is retreating more than 14% <a href="https://investorplace.com/2024/05/why-is-im-cannabis-imcc-stock-up-49-today/">following a rally yesterday</a>.</li>



<li>Plutonian Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/pltn-stock-quote/">PLTN</a>) shares are dropping 14% this morning.</li>



<li>CytomX Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctmx-stock-quote/">CTMX</a>) stock is sliding over 13% after <a href="https://investorplace.com/2024/05/why-is-cytomx-ctmx-stock-up-180-today/">rallying on Wednesday</a>.</li>



<li>DoorDash (NASDAQ:<a href="https://investorplace.com/stock-quotes/dash-stock-quote/">DASH</a>) shares are falling more than 12% <a href="https://apnews.com/article/doordash-earnings-first-quarter-results-175d32378137171b8831c617fa05c70a">despite beating Q1 estimates</a>.</li>



<li>Carver Bancorp (NASDAQ:<a href="https://investorplace.com/stock-quotes/carv-stock-quote/">CARV</a>) stock is decreasing 12% on Thursday.</li>



<li>Wolfspeed (NYSE:<a href="https://investorplace.com/stock-quotes/wolf-stock-quote/">WOLF</a>) shares are down over 11% as <a href="https://finance.yahoo.com/news/wolfspeed-reports-financial-results-third-200500488.html">fiscal Q3 earnings</a> failed to impress investors.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-may-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

PEGY, MTC and IMTE among mid-day movers

SCHMID Group files to sell 57.01M ordinary shares, warrants

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We have all of the biggest pre-market stock movers that traders will want to read about on Monday morning!



Moving stocks this morning an investor update, clinical trial news, a private offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Scinai Immunotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/scni-stock-quote/">SCNI</a>) stock is rocketing more than 69% alongside heavy pre-market trading.</li>



<li>Schmid Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/shmd-stock-quote/">SHMD</a>) shares are soaring 40% without any clear news this morning.</li>



<li>ENDRA Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ndra-stock-quote/">NDRA</a>) stock is surging over 36% alongside an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318395592&amp;type=PDF&amp;symbol=NDRA&amp;cdn=4506ae3b1a739822361489bedc53ef84&amp;companyName=ENDRA+Life+Sciences+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-06-14">investor stake update</a>.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are rising more than 21% with strong early morning trading.</li>



<li>Srivaru (NASDAQ:<a href="https://investorplace.com/stock-quotes/svmh-stock-quote/">SVMH</a>) stock is increasing over 18% as it continues to <a href="https://investorplace.com/2024/06/why-is-srivaru-svmh-stock-up-122-today/">rally on e-bike news</a>.</li>



<li>Nurix Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nrix-stock-quote/">NRIX</a>) shares are gaining 17% on <a href="https://www.marketwatch.com/story/nurix-therapeutics-shares-rise-on-positive-leukemia-drug-results-66b9d524?mod=investing">positive drug results</a>.</li>



<li>Icecure Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/iccm-stock-quote/">ICCM</a>) stock is getting a 14% boost with it still rallying on <a href="https://www.nasdaq.com/press-release/positive-data-icecures-kidney-cancer-clinical-study-presented-interventional">kidney cancer study data</a>.</li>



<li>Kineta (NASDAQ:<a href="https://investorplace.com/stock-quotes/ka-stock-quote/">KA</a>) shares are heading more than 13% higher with heavy trading today.</li>



<li>XTL Biopharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtlb-stock-quote/">XTLB</a>) stock is jumping over 12% this morning.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are up more than 11% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) stock is plummeting more than 35% after a massive rally on Friday.</li>



<li>Sonim Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sonm-stock-quote/">SONM</a>) shares are diving over 25% this morning.</li>



<li>AMC Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/amcx-stock-quote/">AMCX</a>) stock is tumbling more than 23% after <a href="https://www.nasdaq.com/press-release/amc-networks-inc-announces-private-offering-125-million-convertible-senior-notes-2024">announcing a private offering</a>.</li>



<li>Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) shares are taking an over 17% beating despite a lack of news.</li>



<li>Northann (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ncl-stock-quote/">NCL</a>) stock is falling close to 14% without any news to report.</li>



<li>Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) shares are dropping more than 13% as it <a href="https://investorplace.com/2024/06/why-is-zapp-electric-vehicles-zapp-stock-up-173-today/">comes off a rally last week</a>.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) stock is decreasing over 13% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318396271&amp;type=PDF&amp;symbol=APVO&amp;cdn=21e6c068c48621c307f0f74bc8553007&amp;companyName=Aptevo+Therapeutics+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-14">proposed public offering</a>.</li>



<li>Feutune Light Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/flfv-stock-quote/">FLFV</a>) shares are slipping almost 12% on Monday.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is dipping more than 11% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318396398&amp;type=PDF&amp;symbol=VLCN&amp;cdn=980b1d9c3f018f25ac11de4d0e102b66&amp;companyName=Volcon+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-14">a delisting notice</a>.</li>



<li>Holdco Nuvo (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuvo-stock-quote/">NUVO</a>) shares close out our pre-market stock movers down over 11% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-june-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements!



Moving stocks this morning are study data, acquisition updates, a secondary stock offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>SMX (Security Matters) (NASDAQ:<a href="https://investorplace.com/stock-quotes/smx-stock-quote/">SMX</a>) stock is rocketing more than 100% alongside heavy pre-market trading.</li>



<li>Tempest Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/tpst-stock-quote/">TPST</a>) shares are soaring over 50% <a href="https://www.nasdaq.com/press-release/tempest-report-new-data-global-randomized-combination-study-amezalpat-tpst-1120-first">with new study data</a>.</li>



<li>Reliance Global Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) stock is surging close to 35% on <a href="https://www.stocktitan.net/news/RELI/reliance-global-group-provides-update-on-pending-spetner-swj01901tpjv.html">an acquisition update</a>.</li>



<li>Nexalin Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/">NXL</a>) shares are gaining more than 21% without any clear news this morning.</li>



<li>Molecular Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/moln-stock-quote/">MOLN</a>) stock is rising over 17% on Thursday morning.</li>



<li>Denali Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/deca-stock-quote/">DECA</a>) shares are increasing more than 17% in <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318402456&amp;type=PDF&amp;symbol=DECAU&amp;cdn=cb73376de3b0882ecdc7b6dd0bf51177&amp;companyName=Denali+Capital+Acquisition+Corp.+Unit&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-06-18">shareholder meeting plans</a>.</li>



<li>Schmid Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/shmd-stock-quote/">SHMD</a>) stock is climbing over 16% today.</li>



<li>Presto Automation (NASDAQ:<a href="https://investorplace.com/stock-quotes/prst-stock-quote/">PRST</a>) shares are heading more than 16% higher this morning.</li>



<li>Talphera (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlph-stock-quote/">TLPH</a>) stock is jumping over 15% without any obvious news to report.</li>



<li>Aslan Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/asln-stock-quote/">ASLN</a>) shares are up more than 14% on Thursday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Avrobio (NASDAQ:<a href="https://investorplace.com/stock-quotes/avro-stock-quote/">AVRO</a>) stock is crashing over 91% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318400833&amp;type=PDF&amp;symbol=AVRO&amp;cdn=ca84ee38e74b0f6636bad1d41ecb78df&amp;companyName=AVROBIO+Inc.&amp;formType=8-K%2FA&amp;formDescription=%5BAmend%5DCurrent+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-18">merger and reverse stock split news</a>.</li>



<li>NLS Pharmaceutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nlsp-stock-quote/">NLSP</a>) shares are plummeting more than 22% <a href="https://investorplace.com/2024/06/why-is-nls-pharmaceutics-nlsp-stock-up-163-today/">after a recent rally</a>.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) stock is diving over 17% on Thursday.</li>



<li>1847 Holdings (NYSEMKT:<a href="https://investorplace.com/stock-quotes/efsh-stock-quote/">EFSH</a>) shares are taking a more than 17% beating on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318402194&amp;type=PDF&amp;symbol=EFSH&amp;cdn=8afe17ea6c0dfe97988938c03ada1ad9&amp;companyName=1847+Holdings+LLC&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-06-18">proposed secondary stock offering</a>.</li>



<li>La Rosa (NASDAQ:<a href="https://investorplace.com/stock-quotes/lrhc-stock-quote/">LRHC</a>) stock is tumbling over 16% after a <a href="https://www.nasdaq.com/press-release/la-rosa-holdings-corp-announces-plans-acquire-controlling-interest-red-door-title">recent rally on acquisition news</a>.</li>



<li>Huize (NASDAQ:<a href="https://investorplace.com/stock-quotes/huiz-stock-quote/">HUIZ</a>) shares are sliding more than 15% on <a href="https://www.nasdaq.com/press-release/huize-acquires-leading-vietnam-insurtech-platform-global-care-2024-06-20">an acquisition announcemcent</a>.</li>



<li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is falling over 13% <a href="https://investorplace.com/2024/06/why-is-actelis-networks-asns-stock-up-144-today/">after a rally</a>.</li>



<li>N2OFF (NASDAQ:<a href="https://investorplace.com/stock-quotes/nito-stock-quote/">NITO</a>) shares are decreasing more than 13% <a href="https://www.nasdaq.com/press-release/n2off-save-foods-expanding-latin-america-new-purchase-order-peruvian-customer-2024-06">after a similar rally</a>.</li>



<li>Mustang Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/mbio-stock-quote/">MBIO</a>) stock is dropping over 13% <a href="https://investorplace.com/2024/06/why-is-mustang-bio-mbio-stock-up-347-today/">following a rally</a>.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) shares close out our pre-market stock movers down 13% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-20th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements!



Moving stocks this morning are study data, acquisition updates, a secondary stock offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>SMX (Security Matters) (NASDAQ:<a href="https://investorplace.com/stock-quotes/smx-stock-quote/">SMX</a>) stock is rocketing more than 100% alongside heavy pre-market trading.</li>



<li>Tempest Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/tpst-stock-quote/">TPST</a>) shares are soaring over 50% <a href="https://www.nasdaq.com/press-release/tempest-report-new-data-global-randomized-combination-study-amezalpat-tpst-1120-first">with new study data</a>.</li>



<li>Reliance Global Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) stock is surging close to 35% on <a href="https://www.stocktitan.net/news/RELI/reliance-global-group-provides-update-on-pending-spetner-swj01901tpjv.html">an acquisition update</a>.</li>



<li>Nexalin Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/">NXL</a>) shares are gaining more than 21% without any clear news this morning.</li>



<li>Molecular Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/moln-stock-quote/">MOLN</a>) stock is rising over 17% on Thursday morning.</li>



<li>Denali Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/deca-stock-quote/">DECA</a>) shares are increasing more than 17% in <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318402456&amp;type=PDF&amp;symbol=DECAU&amp;cdn=cb73376de3b0882ecdc7b6dd0bf51177&amp;companyName=Denali+Capital+Acquisition+Corp.+Unit&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-06-18">shareholder meeting plans</a>.</li>



<li>Schmid Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/shmd-stock-quote/">SHMD</a>) stock is climbing over 16% today.</li>



<li>Presto Automation (NASDAQ:<a href="https://investorplace.com/stock-quotes/prst-stock-quote/">PRST</a>) shares are heading more than 16% higher this morning.</li>



<li>Talphera (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlph-stock-quote/">TLPH</a>) stock is jumping over 15% without any obvious news to report.</li>



<li>Aslan Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/asln-stock-quote/">ASLN</a>) shares are up more than 14% on Thursday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Avrobio (NASDAQ:<a href="https://investorplace.com/stock-quotes/avro-stock-quote/">AVRO</a>) stock is crashing over 91% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318400833&amp;type=PDF&amp;symbol=AVRO&amp;cdn=ca84ee38e74b0f6636bad1d41ecb78df&amp;companyName=AVROBIO+Inc.&amp;formType=8-K%2FA&amp;formDescription=%5BAmend%5DCurrent+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-18">merger and reverse stock split news</a>.</li>



<li>NLS Pharmaceutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nlsp-stock-quote/">NLSP</a>) shares are plummeting more than 22% <a href="https://investorplace.com/2024/06/why-is-nls-pharmaceutics-nlsp-stock-up-163-today/">after a recent rally</a>.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) stock is diving over 17% on Thursday.</li>



<li>1847 Holdings (NYSEMKT:<a href="https://investorplace.com/stock-quotes/efsh-stock-quote/">EFSH</a>) shares are taking a more than 17% beating on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318402194&amp;type=PDF&amp;symbol=EFSH&amp;cdn=8afe17ea6c0dfe97988938c03ada1ad9&amp;companyName=1847+Holdings+LLC&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-06-18">proposed secondary stock offering</a>.</li>



<li>La Rosa (NASDAQ:<a href="https://investorplace.com/stock-quotes/lrhc-stock-quote/">LRHC</a>) stock is tumbling over 16% after a <a href="https://www.nasdaq.com/press-release/la-rosa-holdings-corp-announces-plans-acquire-controlling-interest-red-door-title">recent rally on acquisition news</a>.</li>



<li>Huize (NASDAQ:<a href="https://investorplace.com/stock-quotes/huiz-stock-quote/">HUIZ</a>) shares are sliding more than 15% on <a href="https://www.nasdaq.com/press-release/huize-acquires-leading-vietnam-insurtech-platform-global-care-2024-06-20">an acquisition announcemcent</a>.</li>



<li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is falling over 13% <a href="https://investorplace.com/2024/06/why-is-actelis-networks-asns-stock-up-144-today/">after a rally</a>.</li>



<li>N2OFF (NASDAQ:<a href="https://investorplace.com/stock-quotes/nito-stock-quote/">NITO</a>) shares are decreasing more than 13% <a href="https://www.nasdaq.com/press-release/n2off-save-foods-expanding-latin-america-new-purchase-order-peruvian-customer-2024-06">after a similar rally</a>.</li>



<li>Mustang Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/mbio-stock-quote/">MBIO</a>) stock is dropping over 13% <a href="https://investorplace.com/2024/06/why-is-mustang-bio-mbio-stock-up-347-today/">following a rally</a>.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) shares close out our pre-market stock movers down 13% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-20th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AMCX

APVO

ASLN

ASNS

ASPN

AVRO

BJDX

BYON

CARV

CONN

CTMX

CVNA

DASH

DECA

DSGN

EFSH

ENVX

EOLS

ETSY

FLFV

FRSH

FSLY

GSUN

HSDT

HUIZ

ICCM

IMCC

IMTE

JELD

KAVL

LRHC

LUNG

MAXN

MBIO

MOLN

MSGM

NDRA

NITO

NLSP

NRIX

NUVO

NUWE

NUZE

PEGY

PLTN

PRST

QLGN

RELI

RELY

SCNI

SELF

SHMD

SONM

STIM

SVMH

SYRA

TACT

TLPH

TPST

TRSG

VLCN

WOLF

XTLB

ZAPP

Press Releases

SCHMID Group Closes Business Combination and Begins Trading on the Nasdaq Stock Exchange

SCHMID Group Takes Next Step Towards Advanced Packaging for Integrated Circuits with Glass Cores

Comments

Schmid Group

Noticias

Últimas noticias sobre Schmid Group (NASDAQ:SHMD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL